Objective To conduct a long‐term, prospective, randomized controlled trial evaluating
rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). …

… We also analyzed retrospectively 195 patients with mixed cryoglobulinemia typified during
1 year at the laboratory of our hospital (MT Mascia, personal communication). Only 31/195 (16…

OBJECTIVE: The objective of this review was to define a core set of recommendations for
the treatment of HCV-associated mixed cryoglobulinemia syndrome (MCS) by combining …

Background To develop preliminary classification criteria for the cryoglobulinaemic syndrome
or cryoglobulinaemic vasculitis (CV). Methods Study part I developed a questionnaire for …

Hepatitis C virus (HCV) chronic infection may be associated with a great number of both
hepatic and extrahepatic manifestations. HCV lymphotropism is responsible for poly-oligoclonal …

Mixed cryoglobulinemia (MC) is a systemic small-vessel vasculitis; B-cell expansion is the
biological substrate of the disease. It can be regarded as benign lymphoproliferative condition …

Objective Some of the manifestations of mixed cryoglobulinemia syndrome (MCS) can be
severe or life-threatening, and should be rapidly contained but, as the therapeutic approaches …

SIR, Thrombosis in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection represents the most relevant extra-pulmonary manifestation of COVID-19 and …

… The recent demonstration of salivary gland epithelial cell infection by human T-lymphtropic
virus-1 (HTLV-1) (47), and previous data concerning the presence of HTLV-1 infection in …

Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic
small-vessel vasculitis characterized by the proliferation of B-cell clones producing …